Skip to main content

camibirstat

Generic: Camibirstat

camibirstat: 3 clinical trials tracked.

camibirstat evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about camibirstat, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Acute Myeloid Leukemia
Clinical Trial Registry Records (3)

A Phase 2 Study of SMARCA4/2 Inhibitor (FHD-286) for POU2F3-Positive Small-Cell Lung Cancer

NCT07551635Registry updated 2026-04-27·Phase 2
Not yet recruiting

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen20 targetStarted 2026-09Completion 2029-011 site · United StatesDana-Farber Cancer Institute

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

NCT07283094Registry updated 2026-03-03·Phase 1
Recruiting

Primary endpoint: Dose-limiting toxicities (DLTs)

Interventionalopen33 targetStarted 2026-02Completion 2030-021 site · United StatesMontefiore Medical Center

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

NCT04891757Registry updated 2025-07-10·Phase 1·FHTX

Primary endpoint: Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments

Interventionalopen144 targetStarted 2021-06Completion 2027-065 sites · United StatesFoghorn Therapeutics Inc.